mm Hg systolic) and included generally healthy older people. The SPRINT trial 4 included a prespecified subgroup analysis of individuals 75 years and older and found that among 2636 patients, intensive treatment was associated with a lower risk of cardiovascular disease and mortality. However, in contrast with the main trial results, there was no association between intensive treatment and adverse events, though these analyses had limited power and included few patients being initiated on treatment for the first time.Observational studies 5 report a lack of association between treatment and mortality in frail older patients with mild hypertension (compared with nonfrail older patients), which suggests any benefits may be limited to healthy older individuals. The OPTiMISE trial 6 is investigating the safety of antihypertensive medication reduction in frail, multimorbid patients 80 years and older and will report in summer 2019. This trial will establish whether medication reduction is possible in such patients without significant rises in blood pressure. If this is the case, future trials could explore whether such an intervention could be used to reduce adverse events in older patients in whom the benefits of treatment may be outweighed by the harms.